By Nick Stride
Friday 7th March 2003
|Text too small?|
Wrightson announced its $1.31-a-share stand in the market on Wednesday and finished the day with 15.05%.
It said its Genesis investment was aimed at "providing an impetus" for more collaboration in agricultural biotechnology.
The move is likely to have been approved by its 19.9% shareholder, Fonterra. Both Wrightson and Fonterra subsidiary RD1 have biotech research arms and market observers have speculated Fonterra will eventually take over Wrightson and separate the rural services and biotech divisions.
Genesis' shares have languished below the $1.70 value of its cash reserves of about $36.3 million. They traded at 97c immediately before the Wrightson stand was announced.
British trials of Genesis' Avac eczema treatment showed the drug to be safe and well-tolerated.
No comments yet
Pushpay buys Colorado rival for US$87.5m
Xero chair to retire early as family’s health comes first
Business leaders quiz finance minister on capacity to spend $12b
House prices are accelerating again, even in Auckland
13th December 2019 Morning Report
Tourists still coming but growth is slowing
Peters backs StuffME merger bid
Supplements, skincare firm poised for reverse listing
NZX, EEX eye carbon auction opportunity
A2 Milk boss steps down, shares fall 7.7%